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ABSTRACT
Background: Recent studies have suggested that mel-
atonin—a hormone produced by the pineal gland
under circadian control—contributes to PD-related
sleep dysfunction. We hypothesized that degenerative
changes to the neural structures controlling pineal
function (especially the suprachiasmatic nuclei of the
anterior hypothalamus) may be responsible for reduced
melatonin output in these patients. We compared
hypothalamic volumes in PD patients with matched
controls and determined whether volume loss corre-
lated with reduced melatonin output in the PD group.
Methods: A total of 12 PD patients and 12 matched
controls underwent magnetic resonance imaging to
determine hypothalamic volume. In addition, PD
patients underwent 24-hour blood sampling in a con-
trolled environment to determine serum melatonin con-
centrations using enzyme-linked immunosorbent
assays.
Results: PD patients had significantly reduced hypo-
thalamic gray matter volume when compared with
matched controls. Melatonin levels were significantly
associated with hypothalamic gray matter volume and
disease severity in PD patients.
Conclusion: Melatonin levels are associated with hypo-
thalamic gray matter volume loss and disease severity
in PD patients. This provides anatomical and physiolog-
ical support for an intrinsic sleep and circadian pheno-
type in PD. VC 2016 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Inter-
national Parkinson and Movement Disorder Society
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Sleep disturbances are one of the most common
nonmotor complaints in Parkinson’s disease (PD) and
have been attributed to a variety of factors. Under-
standing the relative contribution of each is crucial to
identify the most effective treatment strategies for indi-
vidual patients. Some of these relate to the clinically
identified features of the disease such as motor impair-
ment, nocturia, pain, or neuropsychiatric symptoms.
Dopaminergic and other medications may also exacer-
bate patients’ sleep problems. However, the sleep dys-
function in PD may be a result of neuronal loss in key
structures and circuits involved in the regulation of
the sleep-wake cycle.
Two recent studies have reported that reduced mela-
tonin output in PD patients is associated with altered
sleep architecture, including reduced slow wave and
rapid eye movement sleep1 and excessive daytime
sleepiness.2 Altered melatonin patterns have also been
observed in Huntington’s disease3 and Alzheimer’s dis-
ease,4 both of which have prominent sleep and circa-
dian abnormalities. Because melatonin is a hormone
produced by the pineal gland under circadian control,
we hypothesised that degenerative changes to the neu-
ral structures controlling pineal function (especially
the suprachiasmatic nuclei [SCN] of the hypothala-
mus) may reduce melatonin output and contribute to
certain aspects of sleep dysfunction in PD.
This study compared hypothalamic volumes in PD
patients with matched controls and determined
whether volume loss correlated with reduced melato-
nin output in the PD group.
Methods
Patients
A total of 12 PD patients were selected from a pre-
viously studied sleep cohort.1 All of the patients who
had also undergone magnetic resonance imaging
(MRI) as part of the parallel Incidence of Cognitive
Impairment in Cohorts with Longitudinal Evaluation–
Parkinson’s Disease (ICICLE-PD) study were included
in the analysis, in addition to 12 unrelated matched
controls from the Medical Research Council
Cognition and Brain Sciences Unit healthy volunteer
panel. The ICICLE-PD protocol has been published
elsewhere.5 All participants provided written consent,
the study was performed according to the Declaration
of Helsinki, and the protocol was approved by the
local research ethics committee.
In brief, patients underwent a battery of clinical
tests including the Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS), Addenbrooke’s Cognitive Exam-
ination (ACE-R), and the Beck Depression Inventory
(BDI). Levodopa equivalent dose (LED) was calculated
using the conversion factors proposed by Tomlinson
and colleagues.6 Matching was based on age, gender,
years of education, and ACE-R.
Imaging Acquisition and Analysis
MRI data were acquired using a Siemens TIM Trio
3T scanner (Siemens Medical Systems, Erlangen, Ger-
many). Patients underwent T1-weighted magnetisation
prepared rapid gradient echo scanning: pulse repeti-
tion5 2250 ms, echo time5 2.98 ms, flip angle5 9 8,
time delay5 900 ms, 2563256 mm2 field of view,
1923 1 mm slices). Images were preprocessed accord-
ing to a pipeline in SPM8 (http://www.fil.ion.ucl.ac.
uk/spm) run on Matlab 7 (Mathworks, Natick, Mas-
sachusetts). T1-weighted images were segmented into
gray matter and white matter tissue and registered
through the Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra scheme. The
resulting study-specific template was registered to
Montreal Neurological Institute space, and individual
modulated images were smoothed with an 8 mm, full
width at half-maximum Gaussian kernel. A hypothala-
mic region of interest (dilated by 3 mm) from the
H Y P O T H A L A M I C V O L U M E A N D M E L A T O N I N O U T P U T I N P D
Movement Disorders, Vol. 31, No. 7, 2016 1063
WFU Pick Atlas (http://fmri.wfubmc.edu/software/
pickatlas) was used to obtain an individual hypothala-
mic volume per participant (Fig. 1A,B). Gray matter
volume in the region of interest (measured in voxels)
was calculated using the FMRIB Software Library
(FSL) tool “fslstats” within FSL version 4.1.7 (www.
fmrib.ox.ac.uk). Thereafter, relative hypothalamic
gray matter volume was calculated by dividing by
whole brain volume (the sum of the gray and white
matter segments).
Serum Melatonin Measurement
PD patients were admitted to a single room at the
Wellcome Trust Clinical Research Facility at Adden-
brooke’s Hospital in Cambridge. A peripheral venous
cannula was inserted 30 minutes before the start of
sampling at 1:00 PM. During the next 24 hours, partic-
ipants adhered to their habitual bed times, and blood
samples were collected every 90 minutes using a 3-
way valve that was attached to a 0.9% sodium chlo-
ride infusion to prevent the cannula from clotting.
Sampling was performed through a long line to pre-
vent disruption to the patient’s sleep. Participants
remained sedentary apart from bathroom visits. Meal
times were consistent between participants, and no
daytime naps were allowed. Temperature was constant
at 21 8C. Patients were not strictly shielded from exter-
nal light, but lighting levels were less than 5 lux fol-
lowing lights off. Serum melatonin concentrations
were measured using enzyme-linked immunosorbent
assays as previously described.1 Based on hormone
FIG. 1. A and B: Panels show the region of interest used to calculate the hypothalamic volume for each participant. C: Panel is a graphical representa-
tion of the significant reduction in relative hypothalamic gray matter volume in PD patients when compared with matched controls (with standard error
of the mean error bars). D: Panel demonstrates the significant correlation between relative hypothalamic gray matter volume and total 24-hour melato-
nin output (with both axes showing partial residuals). In both graphs, relative hypothalamic gray matter volume was calculated by dividing gray matter
volume by whole brain volume (both measured in voxels). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE 1. Clinical characteristics of PD
patients and controls
Variable PD Controls P valued
Number of participants 12 12 na
Gender ratio (male:female) 6:6 6:6 1.0
Age (years) 66.7 (5.5) 66.3 (5.2) 0.92
Duration of education (years) 18.3 (2.9) 17.2 (2.8) 0.33
ACE-R 95.2 (3.1) 96.1 (3.0) 0.48
Disease duration (years)a 3.3 (1.1) na na
LEDD (mg)b 366 (161) na na
MDS-UPDRS part IIIc 23.9 (9.0) na na
BDI 7.3 (17.8) 3.3 (3.6) 0.011*
*Significant difference at .05 level.
LEDD, levodopa equivalent daily dose; ACE-R, Addenbrooke’s Cognitive
Examination-Revised; MDS-UPDRS, Unified Parkinson’s Disease Rating
Scale; BDI, Beck Depression Inventory; na, not applicable.
Results expressed as mean (SD) unless stated otherwise
*Significant difference at .05 level.
aDisease duration from date of diagnosis.
bAll but two PD patients were taking dopaminergic medication.
cBased on MDS-UPDRS assessments performed within the last 6 months.
dUnpaired t tests performed.
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concentrations at each 90-minute time point, total 24-
hour melatonin output was defined as the area under
the curve (calculated using the trapezoid rule).
Statistical Analysis
All data were approximately normally distributed
based on Shapiro-Wilk testing; therefore, unpaired t
tests were used to compare clinical parameters and
volumetric values between patients and controls. Pear-
son rank correlation testing was used to study the
relationship between melatonin output and relative
hypothalamic gray matter volume, as well as the rela-
tionship between melatonin output and disease sever-
ity (adjusted for LED).
Results
Age, gender, duration of education, and ACE-R
were not significantly different between PD patients
and controls (Table 1). PD patients had a mean dis-
ease duration of 3.3 years, mean LED of 366 mg, and
mean UPDRS part III score of 23.9. None of the par-
ticipants were taking hypnotics. The mean duration
between melatonin testing and MRI in the PD group
was 1.9 months (SD 3.4).
When compared with controls, PD patients had sig-
nificantly reduced relative hypothalamic gray matter
volume (2.563 1027 [SD 2.7831027] vs 2.6931027
[SD 2.073 1027]; P5 .005) (Fig. 1C).
Having verified that there were significant differen-
ces between patients and controls in terms of hypo-
thalamic volume, we found that melatonin levels were
significantly associated with relative hypothalamic
gray matter volume in the PD group (r5 .591,
P5 .028) (Fig. 1D).
Partial correlation between melatonin levels and dis-
ease severity, correcting for LED, showed a significant
inverse relationship (r52.681, P5 .021). There was
no significant relationship between melatonin output
and LED (r5 .180, P5 .76).
Discussion
There is increasing evidence from clinical and ani-
mal studies that there is circadian dysregulation in a
variety of neurodegenerative diseases.7 We previously
reported significant reductions in melatonin concentra-
tion in 30 early-stage PD patients.1 Videnovic and col-
leagues also found a significantly diminished
amplitude of melatonin secretion in serum samples of
20 PD patients on dopaminergic therapy under modi-
fied constant routine conditions.2
There is evidence from neuropathological8 and
imaging9 studies that the hypothalamus is directly
affected by PD. The central clock within the hypothal-
amus, the SCN, is likely to contribute to this volume
loss because it has been shown that mice overexpress-
ing alpha-synuclein exhibit a reduced SCN firing
rate.10 This could weaken their ability to communicate
neural and hormonal signals from the central clock to
the pineal gland, which secretes melatonin into the
blood.
This study thus adds to the existing literature by
suggesting that hypothalamic volume loss—which we
have now shown in this new PD cohort—may be
responsible for reduced melatonin output, which has
been linked to sleep disturbances in PD.
The major limitation of this study is the relatively
small number of patients, which precluded the use of
linear regression and adjustment of confounders. Fur-
thermore, patients were not strictly shielded from exter-
nal light during the melatonin sampling period, which
may have influenced the results. Although we lacked
serum melatonin measurements in the control group,
the critical test for our hypothesis was the correlation
between hypothalamic volume and melatonin levels in
PD patients. It is not yet possible to perform dedicated
imaging of the SCN within the hypothalamus using
3Tesla MRI; therefore, ultra-high field imaging or
clinico-pathological studies will be required to allow
more thorough dissection of the relative role of the dif-
ferent hypothalamic nuclei to this deficit.
In summary, we have shown that melatonin levels are
associated with hypothalamic gray matter volume loss
and disease severity in PD patients. This provides anatom-
ical and physiological support for an intrinsic sleep and
circadian phenotype in PD and the fact that this is related
to the disease itself rather than being an indirect conse-
quence of other symptoms or treatments.
Acknowledgments: We would like to thank Dr. Saber Sami for
his assistance with imaging acquisition and Dr. Noham Wolpe for his
technical support. We would also like to thank the staff at the Wellcome
Trust Clinical Research Facility in Addenbrooke’s Hospital, Cambridge,
for performing the melatonin blood sampling.
References
1. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian
rhythm regulation in early Parkinson disease. JAMA Neurol 2014;
71:589-595.
2. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm
and excessive daytime sleepiness in Parkinson disease. JAMA Neu-
rol 2014;71:463-466.
3. Kakkiolia E, Silajdzic E, Nambron R, et al. Plasma melatonin is
reduced in Huntington’s disease. Mov Disord 2014;29:1511-1515.
4. Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm
disorders in patients with senile dementia of Alzheimer’s type with
disturbed sleep-waking. Biol Psychiatry 1999;45:417-421.
5. Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on
cognition and brain function in newly diagnosed Parkinson’s dis-
ease: ICICLE-PD study. Brain 2014;137:2743-2758.
6. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levo-
dopa dose equivalency reporting in Parkinson’s disease. Mov Dis-
ord 2010;25:2649-2653.
7. Videnovic A, Lazar AS, Barker RA, et al. ‘The clocks that time
us’—circadian rhythms in neurodegenerative disorders. Nat Rev
Neurol 2014;10:683-693.
8. Langston JW, Forno LS. The hypothalamus in Parkinson disease.
Ann Neurol 1978;3:129-133.
H Y P O T H A L A M I C V O L U M E A N D M E L A T O N I N O U T P U T I N P D
Movement Disorders, Vol. 31, No. 7, 2016 1065
9. Politis M, Piccini P, Pavese N, et al. Evidence of dopamine dysfunc-
tion in the hypothalamus of patients with Parkinson’s disease: an in
vivo 11C-raclopride PET study. Exp Neurol 2008;214:112-116.
10. Kudo T, Loh DH, Truong D, et al. Circadian dysfunction in a
mouse model of Parkinson’s disease. Exp Neurol 2011;232:66-75.
GBA Mutations Are Associated
With Earlier Onset and Male Sex
in Dementia With Lewy Bodies
Ana Gamez-Valero, MSc,1,2 Patricia Prada-Dacasa, MSc,1,3
Cristina Santos, PhD,3 Cristina Adame-Castillo, BSc,1
Jaume Campdelacreu, MD,4 Ramon Re~ne, MD,4
Jordi Gascon-Bayarri, MD,4 Lourdes Ispierto, MD,5
Ramiro Alvarez, MD,5 Aurelio Ariza, MD,1 and
Katrin Beyer, PhD1*
1Department of Pathology, Hospital Universitari and Health Sciences
Research Institute Germans Trias i Pujol, Universitat Autonoma de
Barcelona, Barcelona, Spain 2IVECAT Group, Health Sciences
Research Institute Germans Trias i Pujol, Badalona, Spain 3Unitat
d’Antropologia Biologica, Departament de Biologia Animal, Biologia
Vegetal i Ecologia, Universitat Autonoma de Barcelona, Barcelona,
Spain 4Department of Neurology, Hospital Universitari de Bellvitge,
L’Hospitalet de Llobregat, Spain 5Department of Neurology, Hospital
Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Abstract
Background: Parkinson’s disease (PD) and dementia
with Lewy bodies (DLB) are Lewy body diseases char-
acterized by similar pathological features. Several
studies have shown a relation between alterations in
the glucocerebrosidase gene (GBA) and the develop-
ment of LB diseases. Here, we explored the role of
GBA mutations in Spanish DLB patients.
Methods: GBA mRNA sequences were analyzed in a
neuropathological (50 DLB, 43 PD, and 34 control
brains) and in a clinical cohort (47 DLB patients and
131 unaffected individuals).
Results: Sixteen GBA mutation carriers were identified,
5 of which were brains with pure DLB. The most com-
mon mutation, E326K, was strongly associated with pure
DLB and PD with dementia. GBA mutations were overre-
presented in men and associated with earlier DLB onset.
Conclusions: GBA mutations are also an important risk
factor for DLB development in the Spanish population,
are associated with earlier disease onset, and are more
prevalent in men. VC 2015 International Parkinson and
Movement Disorder Society
Key Words: GBA mutations, Parkinson’s disease,
dementia with Lewy bodies
Both Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB) are characterized neuropathologi-
cally by the presence of a-synuclein-immunopositive
Lewy bodies (LBs) in the brain.1 Their morphological
substrate is the same, and although the clinical course
of DLB and PD with dementia (PDD) differs, it is dif-
ficult to detect neuropathological differences between
the 2 conditions. When LB pathology represents the
main neuropathological finding, cases are classified as
pure LB pathology, and when concomitant Alzhei-
mer’s disease (AD) pathology is present as common
LB pathology.2 About 20%-50% of PD patients
develop dementia 10 to 15 years following PD diagno-
sis, and its incidence increases with age and disease
duration.3,4
The lysosomal enzyme glucocerebrosidase (GCase)
is responsible for the breakdown of glucocerebroside
into glucose and ceramide.5 Mutations in the GCase
gene GBA cause GCase deficiency,6 leading to lysoso-
mal glucocerebroside accumulation, resulting in
Gaucher’s disease (GD).5 Because PD is more frequent
in first-degree relatives with GD,7-9 GBA has been
studied in PD and later also in DLB patients, showing
a strong association between GBA mutations and syn-
ucleinopathies.10-16 Two extensive multicenter studies
confirmed the strong association between GBA muta-
tions and PD as well as DLB, with odds ratios of 5.43
and 8.28, respectively.17,18
The reduction of GCase levels in PD is associated
with an increase in abnormal a-synuclein accumula-
tion.16 Two models that aim to explain the role of
GBA mutations for LB disease development are a
gain-of-function model and a loss-of-function model.
Supporting the first hypothesis, GBA mutants were
found to enhance a-synuclein accumulation.19 In the
loss-of-function model, lysosomal glucocerebroside
accumulation directly promoted the formation of a-
synuclein fibrils, which inhibit GCase activity, creating
a bidirectional pathogenic loop.20
Although several studies have shown the association
between GBA mutations and LB diseases in diverse
populations, only 1 work evaluating the role of GBA
mutations in PD has been carried out in the Spanish
population.21 Here, we have characterized GBA
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